• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference
The management of atrial fibrillation (AF) has seen marked changes in past years, with the introduction of new oral anticoagulants, new antiarrhythmic drugs, and the emergence of catheter ablation as a common intervention for rhythm control. Furthermore, new technologies enhance our ability to detect AF. Most clinical management decisions in AF patients can be based on validated parameters that encompass type of presentation, clinical factors, electrocardiogram analysis, and cardiac imaging. Despite these advances, patients with AF are still at increased risk for death, stroke, heart failure, and hospitalizations. During t...
Source: Europace - October 29, 2013 Category: Cardiology Authors: Kirchhof, P., Breithardt, G., Aliot, E., Al Khatib, S., Apostolakis, S., Auricchio, A., Bailleul, C., Bax, J., Benninger, G., Blomstrom-Lundqvist, C., Boersma, L., Boriani, G., Brandes, A., Brown, H., Brueckmann, M., Calkins, H., Casadei, B., Clemens, A., Tags: EHRA CONSENSUS STATEMENT Source Type: research

Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9–10, 2013
The Heart Rhythm Society convened a research symposium on December 9–10, 2013, in Washington, DC, that focused on the prevention of atrial fibrillation (AF) as well as AF-related stroke and morbidity. Attendees sought to summarize advances in understanding AF since a 2008 National Institutes of Health (NIH) conference on this topic1 and to identify continued knowledge gaps and current research priorities. The research symposium also sought to identify key deficiencies and opportunities in research infrastructure, operations, and methodologies.
Source: Heart Rhythm - November 17, 2014 Category: Cardiology Authors: David R. Van Wagoner, Jonathan P. Piccini, Christine M. Albert, Mark E. Anderson, Emelia J. Benjamin, Bianca Brundel, Robert M. Califf, Hugh Calkins, Peng-Sheng Chen, Nipavan Chiamvimonvat, Dawood Darbar, Lee Eckhardt, Patrick T. Ellinor, Derek V. Exner, Source Type: research

Oral Anticoagulants and the Risk of Intracranial Hemorrhage
Conclusions and Relevance Novel oral anticoagulants are uniformly associated with an overall reduced risk of ICH when used for stroke prevention in atrial fibrillation. Any of the currently available NOACs can be considered first line for patients at high risk for ICH.JAMA Neurol. 2013;70(12):1486-1490. doi:10.1001/jamaneurol.2013.4021.
Source: JAMA - December 17, 2014 Category: Journals (General) Source Type: research

Drug Therapy of Apparent Treatment-Resistant Hypertension: Focus on Mineralocorticoid Receptor Antagonists
Abstract Apparent treatment-resistant hypertension (aTRH) is defined as blood pressure (BP) >140/90 mmHg despite three different antihypertensive drugs including a diuretic. aTRH is associated with an increased risk of cardiovascular events, including stroke, chronic renal failure, myocardial infarction, congestive heart failure, aortic aneurysm, atrial fibrillation, and sudden death. Preliminary studies of renal nerve ablation as a therapy to control aTRH were encouraging. However, these results were not confirmed by the Symplicity 3 trial. Therefore, attention has refocused on drug therapy. Secondary forms o...
Source: Drugs - March 19, 2015 Category: Drugs & Pharmacology Source Type: research

CASE 9—2015 Anesthetic Management of a Patient With Esophago-Pericardial Fistula Complicating Atrial Fibrillation Radiofrequency Ablation
ATRIAL FIBRILLATION (AF) REMAINS the most common arrhythmia in the elderly population.1,2 Treatment of AF is tailored toward rhythm and heart rate control using antiarrhythmic medications and anticoagulation therapy to prevent embolic stroke. However, antiarrhythmic therapy fails in a significant number of patients. Drug-refractory AF currently is managed with catheter ablation (CA) procedures, which are associated with a complication rate of about 5% and a mortality rate of approximately 0.001%.
Source: Journal of Cardiothoracic and Vascular Anesthesia - September 16, 2015 Category: Anesthesiology Authors: Michael Essandoh, Andrew J Otey, Juan Crestanello, Jonathan Keshishian, Patrick G. Brady, Rebecca M. Gerlach Tags: Case Conferences Source Type: research

A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference
This report ends with a list of priorities for research in AF patients.
Source: Europace - February 3, 2016 Category: Cardiology Authors: Kirchhof, P., Breithardt, G., Bax, J., Benninger, G., Blomstrom-Lundqvist, C., Boriani, G., Brandes, A., Brown, H., Brueckmann, M., Calkins, H., Calvert, M., Christoffels, V., Crijns, H., Dobrev, D., Ellinor, P., Fabritz, L., Fetsch, T., Freedman, S. B., Tags: EHRA CONSENSUS STATEMENT Source Type: research

Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.
Moorlag M, Mackman N, van der Meijden P, Meijers JCM, Heestermans M, Renné T, Dólleman S, Chayouâ W, Ariëns RAS, Baaten CC, Nagy M, Kuliopulos A, Posma JJ, Harrison P, Vries MJ, Crijns HJGM, Dudink EAMP, Buller HR, Henskens YMC, Själander A, Zwaveling S, Erküner O, Eikelboom JW, Gulpen A, Peeters FECM, Douxfils J, Olie RH, Baglin T, Leader A, Schotten U, Scaf B, van Beusekom HMM, Mosnier LO, van der Vorm L, Declerck P, Visser M, Dippel DWJ, Strijbis VJ, Pertiwi K, Ten Cate-Hoek AJ, Ten Cate H Abstract Atherothrombosis is a leading cause of cardiovascular mortality and long-term morbidity. Platelets and coagu...
Source: Thrombosis and Haemostasis - January 31, 2018 Category: Hematology Authors: Spronk HMH, Padro T, Siland JE, Prochaska JH, Winters J, van der Wal AC, Posthuma JJ, Lowe G, d'Alessandro E, Wenzel P, Coenen DM, Reitsma PH, Ruf W, van Gorp RH, Koenen RR, Vajen T, Alshaikh NA, Wolberg AS, Macrae FL, Asquith N, Heemskerk J, Heinzmann A, Tags: Thromb Haemost Source Type: research

Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference
AbstractThere are major challenges ahead for clinicians treating patients with atrial fibrillation (AF). The population with AF is expected to expand considerably and yet, apart from anticoagulation, therapies used in AF have not been shown to consistently impact on mortality or reduce adverse cardiovascular events. New approaches to AF management, including the use of novel technologies and structured, integrated care, have the potential to enhance clinical phenotyping or result in better treatment selection and stratified therapy. Here, we report the outcomes of the 6th Consensus Conference of the Atrial Fibrillation Net...
Source: Europace - January 2, 2018 Category: Cardiology Source Type: research

Effect of Extensive Ablation on Recurrence in Patients with Persistent Atrial Fibrillation Treated with Pulmonary Vein Isolation (EARNEST-PVI) trial: Design and rationale.
CONCLUSIONS: The EARNEST-PVI trial is a randomized controlled trial designed to assess whether PVI alone is non-inferior to extended substrate ablation for patients with persistent AF undergoing a first catheter ablation. PMID: 30853354 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - March 6, 2019 Category: Cardiology Authors: Dohi T, Nakatani D, Inoue K, Hikoso S, Oka T, Hayashi K, Masuda M, Furukawa Y, Kawasaki M, Egami Y, Kashiwase K, Hirata A, Watanabe T, Miyoshi M, Takeda T, Nakagawa A, Mizuno H, Minamiguchi H, Kitamura T, Suna S, Kojima T, Kida H, Bolrathanak O, Okuyama Y Tags: J Cardiol Source Type: research

The Next Generation of Watchman Just Received CE Mark
Boston Scientific has just received the CE mark for the next generation Watchman FLX Left Atrial Appendage Closure (LAAC) device. The Marlborough, MA-based company said it has initiated a limited market release of the technology in Europe. Watchman LACC devices are intended to reduce the risk of stroke in people with non-valvular Atrial fibrillation. The new Watchman FLX device was designed for simplified implantation to fit a wider range of patients, from those with simple to the most complex anatomies. Boston Scientific said the device allows for implantation flexibility to customize placement with a fully enclosed and r...
Source: MDDI - March 14, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news

Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis.
CONCLUSIONS: Very low- to moderate-certainty evidence suggests no meaningful difference in efficacy outcomes between non-vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonists following percutaneous coronary interventions (PCI) in people with non-valvular atrial fibrillation. NOACs probably reduce the risk of recurrent hospitalisation for adverse events compared with vitamin K antagonists. Low- to moderate-certainty evidence suggests that dabigatran may reduce the rates of major and non-major bleeding, and apixaban and rivaroxaban probably reduce the rates of non-major bleeding compared with vitamin K an...
Source: Cochrane Database of Systematic Reviews - December 18, 2019 Category: General Medicine Authors: Al Said S, Alabed S, Kaier K, Tan AR, Bode C, Meerpohl JJ, Duerschmied D Tags: Cochrane Database Syst Rev Source Type: research

Left Atrial Myxoma Presenting as Cerebral Infarct
ACUTE embolic cerebral stroke is a major health setback for any individual, with increased mortality and morbidity. Embolus arising from cardiac chambers constitutes about 20% of ischemic strokes. Atrial fibrillation is the root cause of more than 50% of cardiogenic emboli, whereas congenital heart diseases, such as atrial septal defect, patent foramen ovale, prosthetic heart valves, rheumatic heart valvular disease, dilated cardiomyopathy, and endocarditis are predisposing factors for cardiogenic emboli.
Source: Journal of Cardiothoracic and Vascular Anesthesia - August 5, 2020 Category: Anesthesiology Authors: Hemant Digambar Waikar, Aylliath Gosalakkal Jayakrishnan, Bodiabaduge Senaka Nimalakeerthi Bandusena, Prakash Priyadarshan, Peter Parthepan Kamalaneson, Abhaya Ileperuma, Praveen Kumar Neema, Richa Dhawan, Mark A. Chaney Tags: Case Conference Source Type: research

Left Atrial Myxoma Presenting as Cerebral Embolism
ACUTE embolic cerebral stroke is a major health setback for any individual, with increased mortality and morbidity. Embolus arising from cardiac chambers constitutes about 20% of ischemic strokes. Atrial fibrillation is the root cause of more than 50% of cardiogenic emboli, whereas congenital heart diseases, such as atrial septal defect, patent foramen ovale, prosthetic heart valves, rheumatic heart valvular disease, dilated cardiomyopathy, and endocarditis are predisposing factors for cardiogenic emboli.
Source: Journal of Cardiothoracic and Vascular Anesthesia - August 5, 2020 Category: Anesthesiology Authors: Hemant Digambar Waikar, Aylliath Gosalakkal Jayakrishnan, Bodiabaduge Senaka Nimalakeerthi Bandusena, Prakash Priyadarshan, Peter Parthepan Kamalaneson, Abhaya Ileperuma, Praveen Kumar Neema, Richa Dhawan, Mark A. Chaney Tags: Case Conference Source Type: research

Left atrial appendage occlusion in haemophilia patients with atrial fibrillation
ConclusionsLAAO is feasible in haemophilia patients with concurrent atrial fibrillation. However, special care including intravenous substitution with coagulation factors must be given in the periprocedural management.
Source: Journal of Interventional Cardiac Electrophysiology - November 25, 2021 Category: Cardiology Source Type: research

Pages: 1  2  3  4  5